508:. The overall goals of the programs comprising Systemic Rheumatic and Autoimmune Diseases are to advance high-quality basic, translational, and clinical research in autoimmune and arthritis-related chronic disorders. These disorders include the adult diseases of rheumatoid arthritis, systemic lupus erythematosus (lupus), scleroderma, vasculitis, the spondyloarthropathies (e.g., ankylosing spondylitis, psoriatic arthritis), gout, fibromyalgia, and Sjögren's syndrome. Pediatric diseases, such as juvenile idiopathic arthritis, periodic fever syndromes, and juvenile lupus are also included. Additionally, the programs support studies focused on the natural history of these disorders, as well as molecular mechanisms of autoimmunity and inflammation, with the goal of finding ways to disrupt them and improve patient outcomes. The NIAMS is committed to pursuing new opportunities in genetics and genomics research, clinical trial design, pain, and biopsychosocial aspects of diseases in this portfolio. It is also committed to identification of risk factors for these disorders, enhancement of disease prediction, and advancement of prevention strategies.
642:
the genetics of skin diseases. Areas of particular emphasis include investigations of stem cells found in skin; studies related to wound healing and fibrosis; heritable disorders of connective tissue (such as Marfan's syndrome); studies related to itch; metabolic studies of skin, such as the effects of hormones and the role of enzymes in skin barrier formation; and immunologically mediated cutaneous disorders, such as atopic dermatitis, contact dermatitis, and vasculitis. Research is underway to better understand keratinizing and inflammatory disorders such as psoriasis and ichthyosis; disorders of pigmentation such as vitiligo; and bullous diseases such as pemphigus, pemphigoid, and epidermolysis bullosa. Other studies encompass acne and the physiologic activity of the sebaceous glands, as well as disorders of the hair, such as alopecia areata. The NIAMS also pursues a deeper understanding of the basic biology of skin functions, new approaches for developing artificial skin, and advances in imaging technologies for diagnosis and tracking of skin disease progression.
531:. The programs comprising Bone Biology and Diseases cover the development of common and rare bone diseases; their prevention, diagnosis, and treatment; and approaches to understanding the genetic, molecular, and cellular mechanisms involved in bone biology. Research areas include the mechanisms of bone formation, resorption, and mineralization; the effects of hormones, growth factors, and other signaling molecules on these processes; genetics, genomics, and epigenetics of bone; bone fracture repair; bone imaging, and determinants of bone quality; and the interaction and communication of bone with other tissues and organs. The programs emphasize the application of fundamental knowledge of bone biology to the development of strategies to prevent bone diseases and bone fractures, as well as therapies for their treatment, while also supporting the characterization of the natural history of osteoporosis and rare bone diseases and disorders, with the ultimate goal of developing better prevention strategies, diagnostic tools, and treatment options for bone diseases.
757:
populations, including new clinical syndromes and trials of new therapies, and houses three sections devoted to cutaneous research areas. The Branch studies signaling pathways that regulate development and maintenance of normal skin, and the changes in these signals that occur during the formation of skin cancer. One area of focus is skin sensory neuroendocrine cells, Merkel cells, and the pathogenesis and treatment of Merkel cell carcinoma (MCC). An important area of research for the Branch includes investigation of the skin microbiome in health and disease. The Branch also aims to extend knowledge of interactions of immune cells in skin and skin appendage niches, combining mouse genetics, bioinformatics, immunology and cell biology. Closely related is the
Laboratory of Skin Biology, which conducts research on the regulation of epidermal differentiation, skin barrier formation, and inflammatory responses associated with barrier dysfunction. A major focus is basic investigation of ectodermal appendage development and the study of human ectodermal dysplasias.
615:. The technology development component includes methods for imaging bone and cartilage to improve the diagnosis and treatment of skeletal disorders, or to facilitate the repair of damage caused by trauma to otherwise healthy musculoskeletal tissues including bone, cartilage, tendon, ligament, intervertebral disc, and meniscus. Therapeutic approaches include drugs, nutritional interventions, joint replacement, bone and cartilage transplantation, and gene therapy. Tissue engineering, regenerative medicine, sports medicine, and musculoskeletal fitness are areas of special emphasis.
202:—The National Arthritis Act (P.L. 93-640) established the National Commission on Arthritis and Related Musculoskeletal Diseases to study the problem of arthritis and to develop an arthritis plan. The act established the position of Associate Director for arthritis and related musculoskeletal diseases and authorized an interagency arthritis coordinating committee; community demonstration project grants; an arthritis data bank; an information clearinghouse; and comprehensive centers for research, diagnosis, treatment, rehabilitation and education.
729:
investigations of socioeconomic and ethnic disparities in health outcomes. The
Clinical Trials and Outcomes Branch also conducts studies on the outcomes of many important orthopaedic conditions. The studies use large clinical databases to investigate rare femur fractures, uncommon hip infections, and novel fracture treatments, as well as studying rare, genetic bone diseases. The goal is to provide clinical insights into conditions that cannot be examined in traditional clinical studies.
401:
311:—The Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education (MD-CARE) Amendments of 2014 (P.L. 113-166) made several changes to the program’s authorization, including expanding the types of muscular dystrophy for which NIH must conduct research, expanding the membership of the MDCC and requiring it to meet two times each year, and expanding the items to be covered in the Action Plan for the Muscular Dystrophies.
698:
Stem Cells and Gene
Regulation, Laboratory of Oral Connective Tissue Biology, Laboratory of Skin Biology, Laboratory of Structural Biology Research, Molecular Immunology and Inflammation Branch, Office of Science and Technology, Pediatric Translational Research Branch, Protein Expression Laboratory, Systemic Autoimmunity Branch, Rheumatology Fellowship and Training Branch, and the Career Development and Outreach Branch
422:
557:, muscle metabolism, and adaptation of muscle to exercise. The programs address a need for translational research to develop discoveries that enhance treatment and improve management of muscle and musculoskeletal diseases and disorders with a focus on the interaction of muscle with other organs and tissues. The overarching objective is to advance the understanding of—and ultimately prevent and treat—
299:—The Omnibus Appropriations Act for FY 2003 (P.L. 108-7) directed Office of the Secretary, HHS, to establish a federal working group on lupus for the purpose of exchanging information and coordinating federal efforts regarding lupus research and education initiatives. NIAMS led this federal working group. The group has representatives from all relevant HHS agencies and other federal departments.
380:
305:—The Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education (MD-CARE) Amendments of 2008 (P.L. 110-361) officially named the related centers of excellence after the senator. In addition, the Muscular Dystrophy Coordinating Committee was authorized to give special consideration to enhance the clinical research infrastructure to test emerging therapies.
236:—The Health Research Extension Act of 1985, P.L. 99-158, established the National Institute of Arthritis and Musculoskeletal and Skin Diseases to increase research emphasis. The legislation provided for the development of a plan for a national arthritis and musculoskeletal diseases program and established two interagency coordinating committees, one on arthritis and
768:
practical, framework for the diagnosis and treatment of human diseases affecting skeletal muscle. The Lab also focuses on dissecting the composition of ribonucleoproteins involved in cellular RNA transport and control of RNA stability, and inflammatory and autoimmune human muscle disease as well as the basic biology of skeletal muscle regeneration.
902:
359:
341:
716:
health partnerships, the Office of the
Clinical Director plays an important role in establishing cutting-edge therapeutic paradigms, in providing medical education in the field of rheumatology, and in reaching out to the community to reduce health care disparities and to improve the understanding of rheumatic and related diseases. The
853:
conducts basic, translational, and clinical research to dissect the pathways involved in the pathogenesis of immune-mediated inflammatory diseases. The mechanisms by which specific gene mutations and polymorphisms predispose to inflammation, and how they contribute to unique phenotypic manifestations
783:
conducts research into the structural basis of the assembly and functioning of macromolecules and their complexes (such as viruses and cytoskeletal proteins), and the mechanisms and proteins that control their assembly. These studies make extensive use of cryoelectron microscopy and three-dimensional
869:
focuses on unraveling the fundamental mechanisms that lead to the development and perpetuation of systemic autoimmune disorders, particularly systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and their associated organ damage. By identifying the mechanisms of tissue damage in SLE and
861:
plans and conducts research on the expression, purification, and structural characterization of human immunodeficiency virus (HIV) and HIV-related proteins. Laboratory scientists also collaborate with NIH intramural researchers studying the structure and function of HIV and HIV-related proteins. The
799:
encompasses an infrastructure of research and support facilities designed to enhance the research capabilities of all IRP scientists. In addition, staff members advise the
Scientific Director, Laboratory and Branch Chiefs, and other key officials on collaborative and cooperative activities, training
748:
The Branch focuses on the TNF-family of cytokines and their receptors, from basic investigation of the trafficking and signaling by these molecules to the study of human diseases involving TNF-family cytokines and their receptors. The Branch also studies intracellular signaling and how this leads to
672:
conducts the initial peer review of specific research applications assigned to the NIAMS. These include applications for
Centers, program projects, single and multi-site clinical trials, scientific conferences, training and career development awards, as well as applications responding to initiatives
641:
The programs comprising Skin
Biology and Diseases support a broad portfolio of basic, translational, and clinical research in skin. These efforts include work on the developmental and molecular biology of skin and skin appendages (such as the hair follicle), the study of skin as an immune organ, and
501:
Spanning the fields of rheumatology, muscle biology, orthopedics, bone and mineral metabolism, and dermatology, the DER is divided into five distinct research areas, each of which encompasses several individual scientific programs. As well, the DER includes an Office of
Extramural Operations (OEO),
497:
The NIAMS Division of
Extramural Research (DER) supports scientific research via grants and contracts in the NIAMS mission areas. Most funding from the NIAMS supports investigators involved in a variety of basic, clinical, epidemiologic, training, and other programs in universities, medical schools,
890:
advises the
Scientific Director, Laboratory and Branch Chiefs, and other key officials within the NIAMS IRP on current and potential training programs; coordinates resources available for NIAMS fellows and their sponsors; and works in partnership with existing NIAMS and NIH components to ensure the
875:
through imaging studies, discovery of novel biomarkers through genomic profiling, and clinical trials of novel therapeutics. The program works closely with the NIH Clinical Center and has established an ongoing collaboration with the international NIH-funded Vasculitis Clinical Research Consortium.
736:
coordinates activities within the NIAMS Community Health Clinic, a health information resource that provides health care services to underserved populations affected by arthritis, lupus, and other rheumatic diseases. The clinic offers patient care with access to specialists, education programs, and
697:
The NIAMS Intramural Research Program (IRP) consists of: Office of the Scientific Director, Office of the Clinical Director, Autoimmunity Branch, Clinical Trials and Outcomes Branch, Community Research and Care Branch, Dermatology Branch, Laboratory of Molecular Immunogenetics, Laboratory of Muscle
688:
provides logistical and operational support for the institute's clinical trial activities. The CMT assesses study risk, implementing data and safety monitoring oversight, tracking enrollment progress, and mitigating study related issues for the complete portfolio of NIAMS funded clinical trials and
882:
is dedicated to the clinical and research training of physicians wishing to pursue careers in biomedical or translational research related to rheumatic diseases. Led by the NIAMS, the NIH Rheumatology Training Program is two years in duration with extensions available for individuals interested in
744:
conducts basic and clinical research on the pathophysiology and treatment of autoimmune diseases. Signal transduction pathways that differentiate normal and pathological immune responses are studied in mouse models and human tissue samples to gain insights into how these processes drive autoimmune
706:
The Office of the Scientific Director is responsible for the development of broad decisions concerning program planning, budget and policy formulation, and resource allocation of the intramural program. The Scientific Director represents the NIAMS in discussions of NIH-wide intramural policies and
715:
The Office of the Clinical Director implements innovative clinical research programs that relate to the broad fields of rheumatologic, musculoskeletal, and skin disorders. Through specific programs in clinical research, rheumatology fellowships and advanced training in translational medicine, and
664:
This Office within the DER manages the NIAMS grants policies and procedures, including oversight of grants administration, scientific review, and clinical management functions. It serves as the primary liaison for the NIAMS with the NIH Office of Extramural Research and with other Institutes that
548:
The programs comprising Muscle Biology and Diseases support a wide range of basic, translational, and clinical research projects in skeletal muscle biology and diseases, with a focus on the fundamental biology of muscle development, physiology, and muscle imaging. Particular interests include the
455:
research; research centers; and research training for scientists within its own facilities as well as grantees at universities and medical schools nationwide. It also supports the dissemination of research results and information through the National Institute of Arthritis and Musculoskeletal and
582:
The programs comprising Joint Biology, Diseases, and Orthopedics focus on understanding the fundamental biology of joints and their component tissues, and on translating this knowledge to a variety of diseases and conditions. Research includes the study of the causes and treatments of acute and
483:
of the NIAMS conducts innovative basic, translational, and clinical research relevant to the health concerns of the institute and provides training for investigators interested in careers in these areas. The ultimate goals are: 1) to provide new insights into the normal function of immune cells,
874:
based in the Systemic Autoimmunity Branch develops clinical and translational research initiatives across many types of systemic vasculitis. The program's key objectives include comprehensive clinical evaluation of patients with known or suspected vasculitis, assessment of vascular inflammation
775:
studies the molecular biology of dental-oral-craniofacial development, with a focus on the teeth, gums, and related jaw structure. The aim of these studies is to understand cells and signals influencing tooth, bone, and periodontal ligament development in order to identify improved regenerative
767:
The Laboratory of Muscle Stem Cells and Gene Regulation investigates the cellular and molecular mechanisms that regulate differentiation and regeneration of skeletal muscle in physiological and pathological conditions. The ultimate goal of these studies is to provide a conceptual, as well as
756:
investigates fundamental and clinical aspects of neoplastic and inflammatory skin disease as well as normal skin function, while also providing all dermatology patient care at the NIH Clinical Center. The Branch includes research focused on clinical and translational research in rare disease
720:
in the Office of the Clinical Director focuses on understanding the mechanisms that underlie human inflammatory disease. Using an approach that integrates genomics, bioinformatics, and mechanistic investigations, the program aims to identify the causes of genetically complex autoinflammatory
164:
The institute also conducts and supports basic research on the normal structure and function of bones, joints, muscles, and skin. Basic research involves a wide variety of scientific disciplines, including immunology, genetics, molecular biology, structural biology, biochemistry, physiology,
728:
conducts research on the health outcomes of patients with rheumatic diseases and orthopaedic conditions. Studies focus on the development and testing of measures of health and disease, identification of predictors of good and poor health outcomes, examination of treatment effectiveness, and
791:
conducts basic and clinical investigations of the molecular mechanisms underlying immune and inflammatory responses in rheumatic and autoimmune diseases. A major focus is the study of receptor-mediated signal transduction and how these processes link to the regulation of genes involved in
784:
image processing in studies of virus infection and replication; renewal of the epidermis, with maintenance of barrier function; prionogenesis (structural transitions of infectious proteins called prions); and intracellular protein quality control by energy-dependent proteases.
484:
bones, muscles, and skin, and diseases that affect them, especially immune and inflammatory diseases; and 2) to generate a cadre of well-trained investigators to continue toward a complete understanding of these structures and the disease conditions that affect them adversely.
891:
quality of incoming trainees at the postdoctoral, post-baccalaureate, and graduate student levels. In addition, the Branch leads Institute career outreach activities, administers the summer internship program, and supports the annual NIAMS Intramural Scientific Training.
883:
advanced research training as NIAMS Scholars in Translational Medicine. The program is accredited by the Accreditation Council for Graduate Medical Education (ACGME), and graduates are eligible to sit for the certifying examination in the subspecialty of rheumatology.
268:
and related conditions, in coordination with other NIH Institutes and the Arthritis and Musculoskeletal Diseases Interagency Coordinating Committee. The institute directed to include resources on juvenile arthritis and associated conditions in its clearinghouse.
218:—The Arthritis, Diabetes, and Digestive Diseases Amendments of 1976 (P.L. 94-562) established the National Arthritis Advisory Board to review and evaluate the implementation of the Arthritis Plan, prepared in response to the National Arthritis Act (P.L. 93-640).
689:
select human subject observational studies with some level of risk. The CMT also implements NIH policies pertaining to clinical trials, in addition to being subject matter experts on Federal Policies for Protection of Human Subjects and FDA regulations.
165:
virology, and pharmacology. Clinical research includes rheumatology, orthopedics, dermatology, metabolic bone diseases, heritable disorders of bone and cartilage, inherited and inflammatory muscle diseases, and sports and rehabilitation medicine.
583:
chronic injuries—including fractures, tendon and ligament injury and repair, and low back pain—as well as clinical and epidemiological studies of osteoarthritis. The program supports developmental and functional investigations of
800:
programs, and proper use of laboratory animals. Staff members also negotiate and facilitate scientific collaborations that involve trans-Institute and trans-NIH initiatives and agreements. The Office includes the following:
906:
463:
supports research supports research via grants and contracts in the Division of Extramural Research. Researchers pursue a wide array of basic, translational, and clinical research and research training in the fields of
1479:
1107:
665:
share research interests. The Office handles scientific integrity and ethical questions in research and manages the NIAMS Advisory Council, a congressionally mandated second tier of the NIH peer review system.
285:—The Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2001, or the MD-CARE Act (P.L. 107-84), called on several components of the NIH, including the NIAMS, to enhance research on
1182:
1172:
680:
works with scientists and institutional research administrators to issue, manage, and close out awards. The branch has legal responsibility for the fiscal management of the institute's extramural grants.
275:—The Lupus Research and Care Amendments of 2000, which passed as part of the Public Health Improvement Act (P.L. 106-505), required NIAMS to expand and intensify research and related activities regarding
254:
and related bone disorders to facilitate and enhance knowledge and understanding on the part of health professionals, patients, and the public through the effective dissemination of information."
1207:
1162:
1435:
1253:
1167:
1212:
1093:
1177:
230:—HHS conferred bureau status on the institute, resulting in the creation of the Division of Arthritis, Musculoskeletal and Skin Diseases and the appointment of a Division Director.
502:
which is responsible for assuring compliance with NIH and NIAMS policies and procedures with regard to scientific review, grants management, and clinical research administration.
1152:
127:
1258:
1192:
870:
RA, the Branch is exploring whether specific pharmacologic interventions that block identified pathways can mitigate complications in these and other immune disorders. The
1147:
1523:
212:
effects of arthritis and musculoskeletal diseases. It laid the groundwork for a national program encompassing research, research training, education and patient care.
1197:
1309:
1268:
1284:
1086:
764:
conducts research on B lymphocytes focusing on the regulation of gene expression and chromatin organization in normal cells and in the setting of cancer.
1222:
845:
provides NIAMS investigators with services, consultative advice, and in-depth instructions in a variety of immunologic methods to interpret immunoassays.
749:
immune-mediated disease. Individuals with known or currently undiagnosed rare genetic syndromes are evaluated by genetic and biochemical investigations.
1031:
934:
911:
1017:
1132:
157:. The institute also disseminates information on research progress in these diseases. NIAMS supports and conducts basic, clinical, translational and
1137:
970:
78:
51:
1518:
1445:
1217:
1079:
707:
programs and serves as the principal advisor to the Director of the NIAMS concerning all ongoing and projected intramural research programs.
1450:
1430:
1248:
1455:
1420:
1294:
1202:
208:—After a year of study and public hearings, the commission issued a comprehensive plan aimed at diminishing the physical, economic and
673:
published by the NIAMS including contract solicitations. Members of the scientific community are selected to serve as peer reviewers.
192:
introduced legislation that would eventually lead to the National Arthritis Act. Companion legislation was introduced in the House by
1238:
406:
224:—P.L. 96-538 changed the name of the institute to the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases.
1187:
176:—An arthritis program was established within the National Institute of Arthritis and Metabolic Diseases under Public Law 81-692.
1425:
511:
The NIAMS Systemic Rheumatic and Autoimmune Diseases research area encompasses the following individual scientific programs:
456:
Skin Diseases Information Clearinghouse and through the NIH Osteoporosis and Related Bone Diseases National Resource Center.
1103:
123:
88:
1243:
137:. The institute investigates the prevention, diagnosis, causes, treatments and cures for both common and rare diseases.
1142:
1061:
618:
The Joint Biology, Diseases and Orthopedics research area encompasses the following individual scientific programs:
745:
diseases, and how therapies that minimize generalized immune suppression can best be developed for these diseases.
1327:
1122:
565:, muscle ion channel diseases, and muscle disorders such as disuse atrophy and age-related loss of muscle mass.
1440:
1362:
917:
498:
academic health centers, and small business concerns, all of which comprise the extramural research community.
250:—The NIH Revitalization Act of 1993 (P.L. 103-43) directed NIAMS to establish "an information clearinghouse on
237:
193:
261:
1352:
1263:
182:—P.L. 92-305 renamed the institute the National Institute of Arthritis, Metabolism, and Digestive Diseases.
1347:
1127:
134:
1367:
1289:
604:
568:
The Muscle Biology and Diseases research area encompasses the following individual scientific programs:
562:
811:
provides state-of-the-art multiparameter analytic and cell sorting capabilities for IRP investigators.
645:
The Skin Biology and Diseases research area encompasses the following individual scientific programs:
534:
The Bone Biology and Diseases research area encompasses the following individual scientific programs:
244:. It also expanded the activities of the National Arthritis Advisory Board to include these diseases.
828:
offers IRP scientists access to light imaging equipment and expertise in light microscopy techniques.
290:
821:
supports all IRP Branches and Laboratories that utilize animal models in their research initiatives.
1372:
608:
448:
427:
364:
265:
64:
862:
Lab serves as a support and resource group for the expression and purification of these proteins.
1397:
992:
558:
554:
469:
286:
1357:
1337:
1322:
1317:
838:
assists with computational and bioinformatics approaches to support NIAMS intramural research.
600:
1382:
1299:
1071:
737:
referral to clinical investigations for the prevention and treatment of rheumatic diseases.
588:
400:
1392:
1377:
1332:
385:
150:
1387:
421:
1512:
241:
189:
154:
465:
452:
251:
209:
158:
279:. Among other provisions, the bill called for information and education programs.
721:
diseases, including systemic juvenile idiopathic arthritis and Behçet's disease.
133:
NIH is the primary federal agency that conducts and supports basic, clinical and
473:
935:"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)"
655:
Skin Repair, Pigmentation and Appendages, Vasculature/Lymphatic Systems Program
1414:
1342:
1062:
Bill Summary & Status 99th Congress (1985 - 1986) H.R.2409 All Information
854:
of individual diseases, are being investigated using a variety of approaches.
379:
1494:
1481:
913:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
20:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
612:
584:
550:
146:
971:"NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases"
264:(P.L. 106-310) directed NIAMS to expand and intensify research programs on
596:
1158:
National Institute of Arthritis and Musculoskeletal and Skin Diseases
592:
116:
National Institute of Arthritis and Musculoskeletal and Skin Diseases
628:
Musculoskeletal Tissue Engineering and Regenerative Medicine Program
161:
research and research training at universities and medical centers.
541:
Clinical, Integrative Physiology, and Rare Diseases of Bone Program
358:
340:
276:
1183:
National Institute of Diabetes and Digestive and Kidney Diseases
1173:
National Institute on Deafness and Other Communication Disorders
538:
Bone Biology, Metabolic Bone Disorders, and Osteoporosis Program
1075:
451:
program of basic, clinical, and translational investigations;
1054:
99:
1208:
National Institute on Minority Health and Health Disparities
952:
1163:
National Institute of Biomedical Imaging and Bioengineering
521:
Scleroderma, Fibrosis, and Autoinflammatory Disease Program
1254:
National Center for Complementary and Integrative Health
1168:
National Institute of Child Health and Human Development
953:"Arthritis, Musculoskeletal and Skin Diseases Home Page"
122:) is one of the institutes and centers that make up the
1213:
National Institute of Neurological Disorders and Stroke
518:
Rheumatic Diseases Integrative Biology Research Program
1436:
National Institutes of Health Director's Pioneer Award
1178:
National Institute of Dental and Craniofacial Research
625:
Clinical Osteoarthritis and Diagnostic Imaging Program
1153:
National Institute of Allergy and Infectious Diseases
1066:
652:
Skin Immunology and Diseases, Skin Microbiome Program
128:
United States Department of Health and Human Services
1259:
National Center for Advancing Translational Sciences
1406:
1308:
1277:
1231:
1193:
National Institute of Environmental Health Sciences
1115:
94:
84:
74:
57:
47:
29:
24:
1148:National Institute on Alcohol Abuse and Alcoholism
1198:National Institute of General Medical Sciences
1269:National Institutes of Health Clinical Center
1087:
145:NIAMS' mission is to support the research of
8:
1285:Advanced Research Projects Agency for Health
789:Molecular Immunology and Inflammation Branch
773:Laboratory of Oral Connective Tissue Biology
19:
880:Rheumatology Fellowship and Training Branch
524:Systemic Autoimmune Disease Biology Program
1094:
1080:
1072:
973:. National Organization for Rare Disorders
611:, with emphasis on contrasting normal and
506:Systemic Rheumatic and Autoimmune Diseases
1133:National Heart, Lung, and Blood Institute
872:Vasculitis Translational Research Program
781:Laboratory of Structural Biology Research
649:Epidermis, Dermis and Skin Senses Program
580:Joint Biology, Diseases, and Orthopedics.
572:Muscle Development and Physiology Program
1138:National Human Genome Research Institute
718:Translational Genetics and Genomics Unit
321:
1524:Medical research institutes in Maryland
1067:National Institutes of Health home page
926:
851:Pediatric Translational Research Branch
622:Cartilage and Connective Tissue Program
79:Department of Health and Human Services
52:Federal Government of the United States
1446:National Center for Research Resources
1218:National Institute of Nursing Research
888:Career Development and Outreach Branch
762:Laboratory of Molecular Immunogenetics
575:Muscle Disorders and Therapies Program
18:
16:United States federal agency division
7:
1451:National Institutes of Health Police
1431:National Institutes of Health campus
1249:John E. Fogarty International Center
1012:
1010:
1008:
1006:
1456:Office of Laboratory Animal Welfare
1421:United States Public Health Service
1295:National Diabetes Education Program
1203:National Institute of Mental Health
939:National Institutes of Health (NIH)
726:Clinical Trials and Outcomes Branch
631:Orthopaedic Implant Science Program
472:, bone and mineral metabolism, and
734:Community Research and Care Branch
14:
1239:Center for Information Technology
702:Office of the Scientific Director
262:The Children's Health Act of 2000
1188:National Institute on Drug Abuse
905: This article incorporates
900:
843:Translational Immunology Section
797:Office of Science and Technology
420:
399:
378:
357:
346:Lawrence E. Shulman, M.D., Ph.D.
339:
1426:Division of Intramural Research
711:Office of the Clinical Director
660:Office of Extramural Operations
555:excitation-contraction coupling
549:basic biology of satellite and
493:Division of Extramural Research
816:Laboratory Animal Care and Use
686:Clinical Management Team (CMT)
678:Grants Management Branch (GMB)
670:Scientific Review Branch (SRB)
319:Directors from 1986 - present
135:translational medical research
1:
1519:National Institutes of Health
1469:indicate acting officeholders
1104:National Institutes of Health
859:Protein Expression Laboratory
124:National Institutes of Health
89:National Institutes of Health
1244:Center for Scientific Review
1223:National Library of Medicine
867:Systemic Autoimmunity Branch
833:Biodata Mining and Discovery
634:Orthopaedic Research Program
546:Muscle Biology and Diseases.
1143:National Institute on Aging
481:Intramural Research Program
1542:
639:Skin Biology and Diseases.
1464:
1123:National Cancer Institute
529:Bone Biology and Diseases
515:Arthritis Biology Program
289:, including establishing
1441:NIH Public Access Policy
918:United States Government
792:inflammatory responses.
476:through these programs.
461:NIAMS Extramural Program
238:musculoskeletal diseases
1353:James Augustine Shannon
1264:Vaccine Research Center
563:inflammatory myopathies
194:Congressman Paul Rogers
1348:William H. Sebrell, Jr
1128:National Eye Institute
907:public domain material
169:Legislative chronology
35:; 38 years ago
1495:39.00140°N 77.09914°W
1368:Donald S. Fredrickson
1290:Visible Human Project
826:Light Imaging Section
613:pathogenic phenotypes
605:infrapatellar fat pad
447:The NIAMS supports a
430:, M.D., M.P.H., D.Sc.
291:centers of excellence
190:Senator Alan Cranston
609:intervertebral discs
559:muscular dystrophies
1500:39.00140; -77.09914
1491: /
1373:James B. Wyngaarden
999:. 15 February 2017.
742:Autoimmunity Branch
693:Intramural Research
585:articular cartilage
488:Extramural research
428:Lindsey A. Criswell
365:Michael D. Lockshin
126:, an agency of the
65:Lindsey A. Criswell
33:August 4, 1986
21:
1398:Monica Bertagnolli
754:Dermatology Branch
468:, muscle biology,
287:muscular dystrophy
266:juvenile arthritis
1474:
1473:
1358:Robert Q. Marston
1338:Lewis R. Thompson
1323:Milton J. Rosenau
1318:Joseph J. Kinyoun
1032:"NIAMS Directors"
1018:"The NIH Almanac"
551:muscle stem cells
449:multidisciplinary
440:
439:
112:
111:
75:Parent department
1531:
1506:
1505:
1503:
1502:
1501:
1496:
1492:
1489:
1488:
1487:
1484:
1383:Harold E. Varmus
1328:John F. Anderson
1300:BRAIN Initiative
1096:
1089:
1082:
1073:
1058:
1057:
1055:Official website
1040:
1039:
1028:
1022:
1021:
1014:
1001:
1000:
989:
983:
982:
980:
978:
967:
961:
960:
949:
943:
942:
931:
921:
904:
903:
424:
407:Robert H. Carter
403:
382:
361:
343:
322:
108:
105:
103:
101:
58:Agency executive
43:
41:
36:
22:
1541:
1540:
1534:
1533:
1532:
1530:
1529:
1528:
1509:
1508:
1499:
1497:
1493:
1490:
1485:
1482:
1480:
1478:
1477:
1475:
1470:
1460:
1402:
1393:Francis Collins
1378:Bernadine Healy
1333:George W. McCoy
1304:
1273:
1227:
1111:
1100:
1053:
1052:
1049:
1044:
1043:
1030:
1029:
1025:
1016:
1015:
1004:
991:
990:
986:
976:
974:
969:
968:
964:
951:
950:
946:
933:
932:
928:
910:
901:
897:
713:
704:
695:
662:
495:
490:
445:
409:, M.D. (Acting)
386:Stephen I. Katz
367:, M.D. (Acting)
317:
171:
151:musculoskeletal
143:
98:
70:
39:
37:
34:
25:Agency overview
17:
12:
11:
5:
1539:
1538:
1535:
1527:
1526:
1521:
1511:
1510:
1472:
1471:
1465:
1462:
1461:
1459:
1458:
1453:
1448:
1443:
1438:
1433:
1428:
1423:
1418:
1410:
1408:
1404:
1403:
1401:
1400:
1395:
1390:
1388:Elias Zerhouni
1385:
1380:
1375:
1370:
1365:
1360:
1355:
1350:
1345:
1340:
1335:
1330:
1325:
1320:
1314:
1312:
1306:
1305:
1303:
1302:
1297:
1292:
1287:
1281:
1279:
1275:
1274:
1272:
1271:
1266:
1261:
1256:
1251:
1246:
1241:
1235:
1233:
1229:
1228:
1226:
1225:
1220:
1215:
1210:
1205:
1200:
1195:
1190:
1185:
1180:
1175:
1170:
1165:
1160:
1155:
1150:
1145:
1140:
1135:
1130:
1125:
1119:
1117:
1113:
1112:
1101:
1099:
1098:
1091:
1084:
1076:
1070:
1069:
1064:
1059:
1048:
1047:External links
1045:
1042:
1041:
1038:. 9 July 2015.
1023:
1020:. 9 July 2015.
1002:
984:
962:
944:
941:. 9 July 2015.
925:
924:
923:
922:
896:
893:
847:
846:
839:
829:
822:
812:
806:Flow Cytometry
712:
709:
703:
700:
694:
691:
661:
658:
657:
656:
653:
650:
636:
635:
632:
629:
626:
623:
577:
576:
573:
543:
542:
539:
526:
525:
522:
519:
516:
494:
491:
489:
486:
444:
441:
438:
437:
434:
431:
425:
417:
416:
415:February 2021
413:
410:
404:
396:
395:
394:December 2018
392:
389:
383:
375:
374:
371:
368:
362:
354:
353:
350:
347:
344:
336:
335:
332:
331:In Office from
329:
326:
316:
313:
309:September 2014
248:September 1993
170:
167:
142:
139:
110:
109:
96:
92:
91:
86:
82:
81:
76:
72:
71:
69:
68:
61:
59:
55:
54:
49:
45:
44:
31:
27:
26:
15:
13:
10:
9:
6:
4:
3:
2:
1537:
1536:
1525:
1522:
1520:
1517:
1516:
1514:
1507:
1504:
1468:
1463:
1457:
1454:
1452:
1449:
1447:
1444:
1442:
1439:
1437:
1434:
1432:
1429:
1427:
1424:
1422:
1419:
1417:
1416:
1412:
1411:
1409:
1405:
1399:
1396:
1394:
1391:
1389:
1386:
1384:
1381:
1379:
1376:
1374:
1371:
1369:
1366:
1364:
1361:
1359:
1356:
1354:
1351:
1349:
1346:
1344:
1341:
1339:
1336:
1334:
1331:
1329:
1326:
1324:
1321:
1319:
1316:
1315:
1313:
1311:
1307:
1301:
1298:
1296:
1293:
1291:
1288:
1286:
1283:
1282:
1280:
1276:
1270:
1267:
1265:
1262:
1260:
1257:
1255:
1252:
1250:
1247:
1245:
1242:
1240:
1237:
1236:
1234:
1230:
1224:
1221:
1219:
1216:
1214:
1211:
1209:
1206:
1204:
1201:
1199:
1196:
1194:
1191:
1189:
1186:
1184:
1181:
1179:
1176:
1174:
1171:
1169:
1166:
1164:
1161:
1159:
1156:
1154:
1151:
1149:
1146:
1144:
1141:
1139:
1136:
1134:
1131:
1129:
1126:
1124:
1121:
1120:
1118:
1114:
1109:
1105:
1097:
1092:
1090:
1085:
1083:
1078:
1077:
1074:
1068:
1065:
1063:
1060:
1056:
1051:
1050:
1046:
1037:
1033:
1027:
1024:
1019:
1013:
1011:
1009:
1007:
1003:
998:
994:
993:"IRP Mission"
988:
985:
972:
966:
963:
958:
954:
948:
945:
940:
936:
930:
927:
919:
915:
914:
908:
899:
898:
894:
892:
889:
884:
881:
876:
873:
868:
863:
860:
855:
852:
844:
840:
837:
834:
830:
827:
823:
820:
817:
813:
810:
807:
803:
802:
801:
798:
793:
790:
785:
782:
777:
774:
769:
765:
763:
758:
755:
750:
746:
743:
738:
735:
730:
727:
722:
719:
710:
708:
701:
699:
692:
690:
687:
682:
679:
674:
671:
666:
659:
654:
651:
648:
647:
646:
643:
640:
633:
630:
627:
624:
621:
620:
619:
616:
614:
610:
606:
602:
598:
594:
590:
586:
581:
574:
571:
570:
569:
566:
564:
560:
556:
552:
547:
540:
537:
536:
535:
532:
530:
523:
520:
517:
514:
513:
512:
509:
507:
503:
499:
492:
487:
485:
482:
477:
475:
471:
467:
462:
457:
454:
453:epidemiologic
450:
442:
435:
433:February 2021
432:
429:
426:
423:
419:
418:
414:
411:
408:
405:
402:
398:
397:
393:
390:
388:, M.D., Ph.D.
387:
384:
381:
377:
376:
372:
370:November 1994
369:
366:
363:
360:
356:
355:
352:October 1994
351:
348:
345:
342:
338:
337:
333:
330:
327:
324:
323:
320:
314:
312:
310:
306:
304:
300:
298:
297:February 2003
294:
292:
288:
284:
283:December 2001
280:
278:
274:
273:November 2000
270:
267:
263:
259:
255:
253:
249:
245:
243:
242:skin diseases
239:
235:
234:November 1985
231:
229:
225:
223:
222:December 1980
219:
217:
213:
211:
207:
203:
201:
197:
195:
191:
187:
183:
181:
177:
175:
168:
166:
162:
160:
159:epidemiologic
156:
155:skin diseases
152:
148:
140:
138:
136:
131:
129:
125:
121:
117:
107:
97:
93:
90:
87:
85:Parent agency
83:
80:
77:
73:
66:
63:
62:
60:
56:
53:
50:
46:
32:
28:
23:
1476:
1466:
1413:
1363:Robert Stone
1157:
1035:
1026:
996:
987:
975:. Retrieved
965:
956:
947:
938:
929:
912:
887:
885:
879:
877:
871:
866:
864:
858:
856:
850:
848:
842:
835:
832:
825:
818:
815:
808:
805:
796:
794:
788:
786:
780:
778:
776:strategies.
772:
770:
766:
761:
759:
753:
751:
747:
741:
739:
733:
731:
725:
723:
717:
714:
705:
696:
685:
683:
677:
675:
669:
667:
663:
644:
638:
637:
617:
589:growth plate
579:
578:
567:
545:
544:
533:
528:
527:
510:
505:
504:
500:
496:
480:
478:
466:rheumatology
460:
458:
446:
412:January 2019
318:
308:
307:
303:October 2008
302:
301:
296:
295:
282:
281:
272:
271:
258:October 2000
257:
256:
252:osteoporosis
247:
246:
233:
232:
227:
226:
221:
220:
216:October 1976
215:
214:
210:psychosocial
205:
204:
200:January 1975
199:
198:
185:
184:
179:
178:
173:
172:
163:
144:
132:
119:
115:
113:
48:Jurisdiction
1498: /
1036:www.nih.gov
474:dermatology
470:orthopedics
391:August 1995
240:and one on
174:August 1950
1513:Categories
1486:77°05′57″W
1483:39°00′05″N
1415:NIH Record
1343:Rolla Dyer
1116:Institutes
977:24 October
895:References
373:July 1995
349:April 1986
206:April 1976
67:, Director
40:1986-08-04
1310:Directors
597:ligaments
315:Directors
147:arthritis
1278:Programs
443:Programs
436:Present
325:Portrait
180:May 1972
1467:Italics
1407:Related
1232:Centers
997:nih.gov
957:nih.gov
836:Section
819:Section
809:Section
601:menisci
593:tendons
141:Mission
130:(HHS).
95:Website
38: (
607:, and
102:.niams
30:Formed
1102:U.S.
909:from
277:lupus
120:NIAMS
1108:list
979:2020
886:The
878:The
865:The
857:The
849:The
841:The
831:The
824:The
814:The
804:The
795:The
787:The
779:The
771:The
760:The
752:The
740:The
732:The
724:The
684:The
676:The
668:The
479:The
459:The
328:Name
228:1982
186:1973
153:and
114:The
106:.gov
104:.nih
334:To
100:www
1515::
1034:.
1005:^
995:.
955:.
937:.
916:.
603:,
599:,
595:,
591:,
587:,
561:,
553:,
293:.
196:.
149:,
1110:)
1106:(
1095:e
1088:t
1081:v
981:.
959:.
920:.
260:—
188:—
118:(
42:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
